Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CPT-11 and Mitomycin C in Advanced Esophageal and Stomach Cancer
NCT00201747Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Sep 2001
- Primary completion
- Oct 2006
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and mitomycin c in esophageal cancer, gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Most efficacious of two combination regimens. Started Sep 2001; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabmitomycin c
03
Conditions
esophageal cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00201747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201747.